Search

Your search keyword '"Queipo de Llano, Maria-Paz"' showing total 9 results
Start Over Author "Queipo de Llano, Maria-Paz"
9 results on '"Queipo de Llano, Maria-Paz"'

1. Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain.

Author

Ribera, Josep-Maria, García, Olga, Buendía-Ureña, Buenaventura, Terol, Maria-José, Vicent, Ana, Vall-Llovera, Ferran, Bergua, Juan, García-Cadenas, Irene, Esteve, Jordi, Ribera, Jordi, Acuña-Cruz, Evelyn, Herrera, Pilar, Hernández-Rivas, Jesus-Maria, Abrisqueta, Pau, González-Campos, José, Rodríguez, Carlos, Bastos-Oreiro, Mariana, Genescà, Eulàlia, Caminos, Nerea, and Queipo de Llano, Maria-Paz

Subjects
HIV infections, BURKITT'S lymphoma
Abstract

This study shows that the clinical and biologic characteristics of adult patients with BL and BLL were similar to those of patients from the BL-IPI cohort. Consequently, the BL-IPI was validated in our series of patients with BL and BLL. Keywords: Burkitt lymphoma; prognosis; International Prognostic Index; validation EN Burkitt lymphoma prognosis International Prognostic Index validation 1993 1996 4 08/22/22 20220801 NES 220801 Chemoimmunotherapy including rituximab and high-dose or infusional chemotherapy constitute the standard treatment for patients with Burkitt's lymphoma (BL) or Burkitt's lymphoma and leukemia (BLL) [[1], [3]]. [Extracted from the article]

Published
2022
Full Text
View/download PDF

2. Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Author

Bataller, Alex, primary, Garrido, Ana, additional, Guijarro, Francesca, additional, Diaz-Beyá, Marina, additional, Oñate, Guadalupe, additional, Hoyos, Montserrat, additional, Arnan, Montserrat, additional, Tormo, Mar, additional, Vives, Susana, additional, Queipo De Llano, Maria Paz, additional, Salamero, Olga, additional, Coll, Rosa, additional, Gallardo, David, additional, Vall-Llovera, Ferran, additional, Escoda, Lourdes, additional, Sampol, Antonia, additional, Garcia-Guiñon, Antonio, additional, Merchan, Brayan, additional, Bargay, Joan, additional, Lopez-Guerra, Monica, additional, Pratcorona, Marta, additional, Zamora, Lurdes, additional, Brunet, Salut, additional, Nomdedeu, Josep F, additional, Sierra, Jorge, additional, and Esteve, Jordi, additional

Published
2020
Full Text
View/download PDF

3. Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials

Author

Ribera, Josep-Maria, primary, Chapchap, Eduardo Cerello, additional, Morgades, Mireia, additional, Genescà, Eulàlia, additional, Gil, Cristina, additional, García-Cadenas, Irene, additional, Barba, Pere, additional, González-Campos, José, additional, Torrent, Anna, additional, Bernal del Castillo, Teresa, additional, Queipo De Llano, Maria Paz, additional, Amigo, María-Luz, additional, Tormo, Mar, additional, Coll, Rosa, additional, Vall-Llovera, Ferran, additional, Ribera, Jordi, additional, Sanchez, Maria Jose, additional, Soria, Beatriz, additional, Cladera, Antonia, additional, Artola, María Teresa, additional, Garcia-Guiñon, Antoni, additional, Giménez Conca, Alberto, additional, Barciela, Lourdes Amador, additional, Ciudad, Juana, additional, and Orfao, Alberto, additional

Published
2020
Full Text
View/download PDF

4. Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival

Author

Garrido, Ana, primary, Hoyos, Montserrat, additional, Diaz-Beyá, Marina, additional, Arnan, Montserrat, additional, Vives, Susana, additional, Calabuig, Marisa, additional, Salamero, Olga, additional, Gallardo, David, additional, Queipo De Llano, Maria Paz, additional, Escoda, Lourdes, additional, Sampol, Antonia, additional, Vall-Llovera, Ferran, additional, Garcia-Guiñon, Antonio, additional, Brayan, Merchan, additional, Bargay, Joan, additional, Torres, J Pio, additional, Ortin, Xavier, additional, Amigo, M Luz, additional, Moraleda, Jose Maria, additional, Falantes, José F., additional, Valcarcel, David, additional, Tormo, Mar, additional, Ribera, Josep-Maria, additional, Brunet, Salut, additional, Sureda Balari, Anna, additional, Esteve, Jordi, additional, and Sierra, Jorge, additional

Published
2020
Full Text
View/download PDF

5. Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease

Author

Sierra, Jorge, primary, Garrido, Ana, primary, Diaz Beya, Marina, primary, Hoyos, Montserrat, primary, Calabuig, Marisa, primary, Vives, Susana, primary, Arnan Sangerman, Montserrat, primary, Queipo De Llano, Maria Paz, primary, Salamero, Olga, primary, Vall-Llovera, Ferran, primary, Bataller, Alex, primary, Guijarro, Francisca, primary, Escoda, Lourdes, primary, Garcia-Guiñon, Antonio, primary, Merchan, Brayan, primary, Ortin, Xavier, primary, Sanchez Ortega, Isabel, primary, Pratcorona, Marta, primary, Bargay, Joan, primary, Sampol, Antonia, primary, Nomdedeu, Josep, primary, Gallardo, David, primary, Ribera, Josep-Maria, primary, Tormo, Mar, primary, Esteve, Jordi, primary, and Brunet, Salut, primary

Published
2019
Full Text
View/download PDF

6. Prognostic Impact of the Interaction between DNMT3A mutation and Internal Tandem Duplication of the FLT3 Gene (FLT3-ITD) in Patients with De Novo Mutated NPM1 (NPM1mut) acute Myeloid Leukemia

Author

Oñate, Guadalupe, primary, Garrido, Ana, additional, Esteve, Jordi, additional, Coll, Rosa, additional, Arnan Sangerman, Montserrat, additional, Vives, Susana, additional, Sampol, Antonia, additional, Tormo, Mar, additional, Escoda, Lourdes, additional, Queipo De Llano, Maria Paz, additional, Garcia-Guiñon, Antoni, additional, Bargay, Joan, additional, Salamero, Olga, additional, Aljarilla, Alba, additional, Brunet, Salut, additional, Sierra, Jorge, additional, Nomdedeu, Josep, additional, and Pratcorona, Marta, additional

Published
2018
Full Text
View/download PDF

7. Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years

Author

Sierra, Jorge, Garrido, Ana, Vives, Susana, Queipo De Llano, Maria Paz, Guàrdia, Ramon, Diaz-Beyá, Marina, Calabuig, Marisa, Pratcorona, Marta, Arnan Sangerman, Montserrat, Salamero, Olga, Cervera, Marta, Sampol, Antonia, Garcia-Guiñon, Antoni, Pedro, Carme, Marti, Josep M, Bargay, Joan, Font, Llorenç, Nomdedeu, Josep F, Hoyos, Montserrat, Escoda, Lourdes, Batlle, Montserrat, Merchan, Bryan, Sanchez-Ortega, Isabel, Tormo, Mar, Gallardo, David, Ribera, Josep-Maria, Esteve, Jordi, and Brunet, Salut

Published
2017
Full Text
View/download PDF

8. Complex Measurements May Be Required to Establish the Prognostic Impact of Immunophenotypic Markers in AML.

Author

García-Dabrio, Maria Concepcion, Hoyos, Montserrat, Brunet, Salut, Tormo, Mar, Ribera, Josep-Maria, Esteve, Jordi, Gallardo, David, Duarte, Rafael F., Queipo de Llano, Maria Paz, Bargay, Joan, Martí-Tutusaus, Josep M., Heras, Inmaculada, Garcia, Antoni, Salamero, Olga, Aventin, Anna, Lecrevisse, Quentin, Orfao, Alberto, Sierra, Jorge, and Nomdedéu, Josep F.

Subjects
ACUTE myeloid leukemia, IMMUNOPHENOTYPING, LEUKEMIA, FLOW cytometry, PROTEIN expression, PROGNOSIS
Abstract

Objectives: The prognostic impact of immunophenotypic markers in acute myeloid leukemia (AML) is controversial. Methods: We retrospectively analyzed the value of CD34, CD117, CD7, and CD123 expression in a consecutive series of 592 adult patients with de novo AML. Results: CD34+ measured as a percentage (≥2.88%) and CD34 mean fluorescence intensity (MFI) (≥146.79, arbitrary units [AU]) expression had a prognostic impact in terms of overall survival (OS; P = .005, P = .003), leukemia-free survival (LFS; P = .011, P < .001), and cumulative incidence of relapse (CIR; P = .014, P =. 001). The percentage of CD117+ cells (61.29%) was associated with shorter LFS (P =. 043), and CD117 MFI (≥284.01 AU) was associated with a shorter OS (P =. 033) and LFS (P =. 028). In the multivariate analysis, high CD34 MFI retained the independent value as predictor of LFS and CIR (P =. 012; hazard ratio [HR], 1.59; 95% confidence interval [CI], 1.11- 2.28 and P =. 045; HR, 1.58; 95% CI, 1.01-2.46). Conclusions: CD34 positivity threshold with prognostic relevance is low (3% positive cells). Immunophenotypic findings in AML probably could only be fully exploited after a complex analysis that takes into account unconventional thresholds and the MFI. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

9. Prognostic Impact of the Interaction between DNMT3Amutation and Internal Tandem Duplication of the FLT3Gene (FLT3-ITD)in Patients with De NovoMutated NPM1 (NPM1mut) acute Myeloid Leukemia

Author

Oñate, Guadalupe, Garrido, Ana, Esteve, Jordi, Coll, Rosa, Arnan Sangerman, Montserrat, Vives, Susana, Sampol, Antonia, Tormo, Mar, Escoda, Lourdes, Queipo De Llano, Maria Paz, Garcia-Guiñon, Antoni, Bargay, Joan, Salamero, Olga, Aljarilla, Alba, Brunet, Salut, Sierra, Jorge, Nomdedeu, Josep, and Pratcorona, Marta

Abstract

Introduction

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results